Title: Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Journal: Laboratory investigation; a journal of technical methods and pathology20121001
Title: Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
Journal: Journal of medicinal chemistry20120524
Title: Suppression of Etk/Bmx protects against ischemic brain injury.
Journal: Cell transplantation20120101
Title: Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines.
Journal: The Journal of allergy and clinical immunology20120101
Title: Essential role of Stat3 in PI3K-induced oncogenic transformation.
Journal: Proceedings of the National Academy of Sciences of the United States of America20110809
Title: Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages.
Journal: Journal of immunology (Baltimore, Md. : 1950)20110715
Title: In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
Journal: Arzneimittel-Forschung20110101
Title: Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
Journal: Bioorganic & medicinal chemistry letters20101101
Title: Tec protein tyrosine kinase inhibits CD25 expression in human T-lymphocyte.
Journal: Immunology letters20100104
Title: ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds.
Journal: Bioorganic & medicinal chemistry20090201
Title: Tec kinases regulate actin assembly and cytokine expression in LPS-stimulated human neutrophils via JNK activation.
Journal: Cellular immunology20090101
Title: Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening.
Journal: Journal of medicinal chemistry20081211
Title: Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium.
Journal: Cancer research20080415
Title: Role of different protein tyrosine kinases in fMLP-induced neutrophil transmigration.
Journal: Immunobiology20080101
Title: A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Journal: Proceedings of the National Academy of Sciences of the United States of America20071218
Title: Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases.
Journal: Cell cycle (Georgetown, Tex.)20071215
Title: Characterization of the intracellular mechanisms involved in the antiaggregant properties of cinnamtannin B-1 from bay wood in human platelets.
Journal: Journal of medicinal chemistry20070809
Title: Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Journal: Bioorganic & medicinal chemistry20070115
Title: Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
Journal: Arzneimittel-Forschung20070101
Title: Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate.
Journal: Arzneimittel-Forschung20070101
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology20060501
Title: Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.
Journal: European journal of immunology20060501
Title: Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases.
Journal: Journal of leukocyte biology20050801
Title: Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Journal: British journal of haematology20040901
Title: The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
Journal: Biological chemistry20040501
Title: In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.
Journal: Arzneimittel-Forschung20040101
Title: The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Journal: Leukemia & lymphoma20030901
Title: Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.
Journal: Journal of immunology (Baltimore, Md. : 1950)20030515
Title: BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells.
Journal: Oncogene20030417
Title: Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease.
Journal: Antiviral research20021201
Title: Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA).
Journal: FEBS letters20020911
Title: In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20020501
Title: Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
Journal: The Journal of biological chemistry20020419
Title: Tyrosine kinase inhibitors against EGF receptor-positive malignancies.
Journal: Methods in molecular biology (Clifton, N.J.)20010101
Title: Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Journal: The Journal of biological chemistry19990402
Title: Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide J Biol Chem. 1999 Apr 2;274(14):9587-99.
Title: van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13.
Title: "Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2017 Nov 15."
Title: Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26.
